Blueprint Medicines Completes Acquisition of Lengo ...
www.biospace.com › article › releases1 day ago · CAMBRIDGE, Mass., Dec. 30, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 ...
Blueprint Medicines
www.blueprintmedicines.comBlueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations
Blueprint Medicines
https://www.blueprintmedicines.comBlueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations